(NASDAQ: RYTM) Rhythm Pharmaceuticals's forecast annual revenue growth rate of 76.01% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Rhythm Pharmaceuticals's revenue in 2026 is $174,334,000.On average, 17 Wall Street analysts forecast RYTM's revenue for 2026 to be $20,086,218,135, with the lowest RYTM revenue forecast at $17,029,039,410, and the highest RYTM revenue forecast at $23,157,411,432. On average, 12 Wall Street analysts forecast RYTM's revenue for 2027 to be $36,883,683,430, with the lowest RYTM revenue forecast at $29,103,594,022, and the highest RYTM revenue forecast at $47,376,593,515.
In 2028, RYTM is forecast to generate $66,547,192,962 in revenue, with the lowest revenue forecast at $45,780,934,416 and the highest revenue forecast at $81,217,780,152.